EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Dioscin Ameliorates Experimental Autoimmune Thyroiditis via the mTOR and TLR4/NF-κB Signaling

Chengfei Zhang iD, Qiue Zhang iD, Lingling Qin, Zhiyi Yan iD, Lili Wu, Tonghua Liu iD

Drug Design, Development and Therapy · 2023-08 · Volume 17 · 2273-2285

DOI: 10.2147/dddt.s410901 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2023-08. Verfasst von Chengfei Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Beijing University of Chinese Medicine, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Hashimoto Disease, Thyroiditis, Autoimmune. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Autoimmune thyroiditis (AIT) is a common autoimmune disease that causes thyroid dysfunction. Clinical symptoms in Hashimoto thyroiditis patients were improved after oral administration of dioscin. However, the mechanisms involved in the therapeutic effect remain unclear.

Methods

The protective effects and potential mechanisms of dioscin for autoimmune thyroiditis were explored in a rat model of thyroglobulin-induced autoimmune thyroiditis. Firstly, the rat model of AIT was obtained by subcutaneous injection of thyroglobulin and drinking the sodium iodide solution, followed by gavage administration for 8 weeks. Rats were sacrificed after anaesthesia, serum and thyroid samples were preserved. Serum triiodothyronine (T3), thyroxine (T4), free triiodothyronine (FT3), free thyroxine (FT4), thyrotropin (TSH), thyroglobulin antibody (TgAb), thyroid peroxidase antibody (TPOAb), and thyrotropin receptor antibody (TRAb) expressions were measured by enzyme-linked immunosorbent assay (ELISA). Morphological changes were observed by H&E staining. Next, we used transcriptomics techniques to find the potential therapeutic target of dioscin. Finally, we validated the transcriptomic results by reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC-P), respectively.

Results

Animal experiments showed that dioscin regulated T3, T4, FT3, TSH, TgAb, TPOAb, and TRAb and alleviated the pathological process in a dose-dependent manner, with the high-dose group showing optimal efficacy. In the transcriptome, the nuclear factor kappa B (NF-κB) pathway was identified by KEGG enrichment analysis and validated by RT-PCR and IHC-P. The relative expression of NF-κB, mechanistic target of rapamycin (mTOR), and toll-like receptor 4 (TLR4) mRNA and protein were decreased in the dioscin-treated group compared to the AIT model group.

Conclusion

Our results suggest that dioscin treatment improved thyroid function and downregulated TGAb, TPOAb and TRAb levels in rat models of AIT, which may alleviate the pathological process and suppress the inflammatory response by inhibiting mTOR and TLR4/NF-κB pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hashimoto DiseaseThyroiditis, AutoimmuneAnimalsRatsAutoantibodiesNF-kappa BThyroglobulinThyrotropinThyroxineToll-Like Receptor 4TOR Serine-Threonine KinasesTriiodothyronineDiosgenin

Stichwörter der Autor:innen

TLR4/NF-κBautoimmune thyroiditisdioscintranscriptome

Substanzen

AutoantibodiesNF-kappa BThyroglobulinThyrotropinThyroxineToll-Like Receptor 4TOR Serine-Threonine KinasesTriiodothyroninedioscinDiosgenin

Autor:innen und Institutionen

  • School of Life Sciences, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
  • Dongfang Hospital of Beijing University of Chinese Medicine, Beijing, People's Republic of China.
  • School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
  • Technology Department, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
  • Key Laboratory of Health Cultivation of the Ministry of Education, Beijing University of Chinese Medicine, Beijing, People's Republic of China.

ORCID-Profile: Chengfei Zhang, Qiue Zhang, Zhiyi Yan, Tonghua Liu

Zitieren

APA

Zhang, C., Zhang, Q., Qin, L., Yan, Z., Wu, L., & Liu, T. (2023). Dioscin Ameliorates Experimental Autoimmune Thyroiditis via the mTOR and TLR4/NF-κB Signaling. Drug Design, Development and Therapy, Volume 17, 2273-2285. https://doi.org/10.2147/dddt.s410901

Vancouver

Zhang C, Zhang Q, Qin L, Yan Z, Wu L, Liu T. Dioscin Ameliorates Experimental Autoimmune Thyroiditis via the mTOR and TLR4/NF-κB Signaling. Drug Design, Development and Therapy. 2023;Volume 17:2273-2285. doi:10.2147/dddt.s410901

BibTeX
@article{Zhang2023,
  author = {Zhang, Chengfei and Zhang, Qiue and Qin, Lingling and Yan, Zhiyi and Wu, Lili and Liu, Tonghua},
  title = {Dioscin Ameliorates Experimental Autoimmune Thyroiditis via the mTOR and TLR4/NF-κB Signaling},
  journal = {Drug Design, Development and Therapy},
  year = {2023},
  volume = {Volume 17},
  pages = {2273--2285},
  doi = {10.2147/dddt.s410901}
}
Kostenlos starten →